Cassava Sciences Inc.’s stock crated 85% in premarket trade Monday, after the clinical-stage biotech said a trial of a ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...

Modeled after the state’s $6B cancer research fund, the dementia fund could pump hundreds of millions of dollars into Texas ...

Alzheimer’s disease affects more than 50 million people worldwide, often devastating both the individuals who have it and ...

Cassava Sciences Inc.'s stock (SAVA) was halted after falling 5% in premarket trade Monday, after the company said a trial of a treatment for mild-to-moderate Alzheimer's disease failed to meet its ...

The risk of Alzheimer's disease can be decreased by making healthy food choices, suggested a new study.Research done by a ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study Simufilam contin ...

In this new analysis, the Company reported changes in plasma biomarkers that may reflect Alzheimer's disease pathology. The results demonstrated that individuals who entered the study with plasma ...

We join Dr. Sheona Scales, Director of Research at Alzheimer’s Research UK, to discuss why the ARUK Research Conference is an ...

The project will test blood and urine samples collected from thousands of people over decades, looking for traces of ...